Orchard Therapeutics is being bought at a massive premium
Invezz
Published Oct 05, 2023 15:38
Updated Oct 05, 2023 16:12
Orchard Therapeutics is being bought at a massive premium
Shares of Orchard Therapeutics (NASDAQ: ORTX) almost doubled this morning after Kyowa Kirin Co Ltd (TYO: 4151) announced plans of buying the gene therapy company.
Details of Orchard-Kyowa definitive agreement/h2
The Japanese specialty pharmaceutical firm is willing to spend about $387.4 million on the acquisition.
The definitive agreement values each American Depository Share (ADS) of Orchard Therapeutics at $16 – close to a 100% premium on their previous close. According to Takeyoshi Yamashita – the Chief Medical Officer of Kyowa Kirin:
Our hope is to combine with mutual respect to realise the successful creation and delivery of life-changing value for patients living with rare and life-threatening inherited diseases.
The announcement arrives more than two months after Orchard Therapeutics reported $7.3 million in revenue for its second financial quarter.
Kyowa may end up paying $17 per share instead/h2
Orchard Therapeutics is currently awaiting U.S. approval for its treatment of metachromatic leukodystrophy that it calls OTL-200.
If approved, the unlocked “contingent value rights” will increase the overall valuation of this deal to about $477.6 million or $17 per share. Yamashita of Kyowa Kirin also said in a press release today:
With this transaction, we anticipate being able to use a new modality that can have a profound impact on patients’ lives. ORTX has already launched its HSC gene therapy in Europe.
The Japanese specialty pharmaceutical company expects this transaction to complete in the first quarter of 2024. Kyowa Kirin will get to further strengthen its leading position in genetic medicine via this merger.
The post Orchard Therapeutics is being bought at a massive premium appeared first on Invezz.
This article first appeared on Invezz.com
Get The App
Written By: Invezz
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.